The Mundipharma global network of privately-owned independent associated companies operates in more than 120 countries.
Per the agreement, Mundipharma will be responsible for the sale, marketing and promotion of Janssen Pharmaceutica NV’s Invokana (canagliflozin) and Vokanamet (a fixed-dose combination therapy of canagliflozin and metformin).
"Developing strong partnerships is at the heart of what we do at Mundipharma and the expanded agreement with Janssen is testimony to this," Chris Surridge, head of commercial excellence at Mundipharma told Outsourcing-Pharma.com.
"The priority is to ensure a smooth transition with Janssen in the relevant markets," Surridge added. As for next steps, he said they include "galvanizing our primary care team, getting them up to speed as quickly as possible in order to get these medicines to patients that need them."
Janssen has secured reimbursement for both the products in 14 of the 17 European markets and expects to add the remaining three in the upcoming months, according to the company.
Alberto Martinez, European director of commercial operations at Mundipharma commented in the press release: “We envisage increased expansion over the next decade by seeking further alliances, with companies with innovative primary care medicines being key to that growth.”
Janssen retains manufacturing responsibilities for the products and responsibility for some regulatory activities in collaboration with Mundipharma, including pharmacovigilance and marketing authorization updates.